Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Vogl

Showing results (331-340 of 342) with videos related to

Pageof 35
Sort By:
Leukemia|February 26, 2020
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trialsMaria Gavriatopoulou, Ajai Chari, Christine Chen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 22, 2014
Older patients with myeloma derive similar benefit from autologous transplantationManish Sharma, Mei-Jie Zhang, Xiaobo Zhong, et al.
Nature Medicine|January 24, 2024
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapyGuido Ghilardi, Joseph A Fraietta, James N Gerson, et al.
Nature Medicine|July 21, 2015
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myelomaAaron P Rapoport, Edward A Stadtmauer, Gwendolyn K Binder-Scholl, et al.
Blood Cancer Discovery|November 22, 2022
Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line TherapyAlfred L Garfall, Adam D Cohen, Sandra P Susanibar-Adaniya, et al.
The New England Journal of Medicine|August 22, 2019
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple MyelomaAjai Chari, Dan T Vogl, Maria Gavriatopoulou, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 10, 2013
Salvage second hematopoietic cell transplantation in myelomaLaura C Michaelis, Ayman Saad, Xiaobo Zhong, et al.
Bone Marrow Transplantation|August 25, 2015
Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantationG L Uy, L J Costa, P N Hari, et al.
Nature Medicine|January 15, 2026
CD4<sup>+</sup> T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapyMatthew Ho, Luca Paruzzo, Julia Han Noll, et al.
Zeitschrift Fur Gastroenterologie|February 11, 2022
M Bitzer, S Voesch, J Albert, et al.
Pageof 35

Showing results (331-340 of 342) with videos related to

Sort By:
Pageof 35
Leukemia|February 26, 2020
Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trialsMaria Gavriatopoulou, Ajai Chari, Christine Chen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 22, 2014
Older patients with myeloma derive similar benefit from autologous transplantationManish Sharma, Mei-Jie Zhang, Xiaobo Zhong, et al.
Nature Medicine|January 24, 2024
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapyGuido Ghilardi, Joseph A Fraietta, James N Gerson, et al.
Nature Medicine|July 21, 2015
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myelomaAaron P Rapoport, Edward A Stadtmauer, Gwendolyn K Binder-Scholl, et al.
Blood Cancer Discovery|November 22, 2022
Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line TherapyAlfred L Garfall, Adam D Cohen, Sandra P Susanibar-Adaniya, et al.
The New England Journal of Medicine|August 22, 2019
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple MyelomaAjai Chari, Dan T Vogl, Maria Gavriatopoulou, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 10, 2013
Salvage second hematopoietic cell transplantation in myelomaLaura C Michaelis, Ayman Saad, Xiaobo Zhong, et al.
Bone Marrow Transplantation|August 25, 2015
Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantationG L Uy, L J Costa, P N Hari, et al.
Nature Medicine|January 15, 2026
CD4<sup>+</sup> T cells mediate CAR-T cell-associated immune-related adverse events after BCMA CAR-T cell therapyMatthew Ho, Luca Paruzzo, Julia Han Noll, et al.
Zeitschrift Fur Gastroenterologie|February 11, 2022
M Bitzer, S Voesch, J Albert, et al.
Pageof 35